Sphere Fluidics expands to increase supply of surfactant for droplet microfluidics
Investment in resources to meet demand for large-scale supply of patented biocompatible surfactant.
Sphere Fluidics has announced an investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf, for reliable and highly stable droplet generation and processing. Sphere Fluidics will expand operations to meet demand for large-scale commercial supply of its high-performing surfactant for use in a wide range of microfluidic application workflows.
Pico-Surf is a high-quality and animal-origin-free biocompatible surfactant optimized to support the formation of aqueous solution-in-oil picodroplets. Sphere Fluidics aims to increase production of Pico-Surf by three-fold in 2020, while maintaining its industry-leading standards, through significant investment of resources in manufacture and quality control processes, and workforce. As part of the company's range of specialist chemicals, Pico-Surf is designed to work effectively and flexibly across a broad range of microfluidic systems, including the Sphere Fluidics' proprietary single cell analysis platforms and applications, such as molecular biology assays, cell secretion assays and cell growth studies.
The unique and patented molecular structure of Pico-Surf stabilizes droplets, and retains and protects their cellular and molecular contents over a wide range of temperatures and biological conditions, helping to ensure high cell viability for improved assay performance. Droplets generated using Pico-Surf show low end point interfacial tension and critical micelle concentration in comparison to other commercially available surfactants. The purity and quality of the surfactant also enables a more efficient droplet sorting process at low voltage. The ready-to-use surfactant is available in large batches or made-to-order with ensured lot-to-lot consistency.
Dr Marian Rehak, Vice President of Research and Development, Sphere Fluidics, said: “We are enthused by the increased demand for Pico-Surf, and eager to mobilize its production to meet demand. While doing so, we will ensure its very high-quality control standards are maintained, meaning researchers can continue to rely on Pico-Surf to create droplets that are stable and reproducible.”
Rob Treanor, Director of Operations, Sphere Fluidics, commented: “Sphere Fluidics’ world-leading expertise in picodroplet technology has enabled the development of an ever-growing range of high-performing patented consumables, vital for the successful use of microfluidic systems. All our consumable products have been designed to be platform-agnostic, so they work effectively with a number of microfluidic systems.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance